Drug interactions
Dihydroergotamine intranasal + Nicardipine
Severity: Major
Dihydroergotamine intranasal and Nicardipine: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Dihydroergotamine is cleared mainly by CYP3A4, and raised concentrations carry a risk of severe peripheral and cerebral vasospasm and ischemia. Nicardipine is only a modest CYP3A4 inhibitor, but the narrow safety margin of ergot toxicity makes the combination hazardous.
What this interaction means in plain words
Dihydroergotamine intranasal and Nicardipine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Nicardipine inhibition of CYP3A4 reduces dihydroergotamine clearance, increasing ergot vasoconstrictive effects.
What to do
Avoid if possible and use an alternative migraine therapy. If used together, monitor for ischemic symptoms such as limb coldness, numbness and chest pain, and stop dihydroergotamine if they occur.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dihydroergotamine intranasal and Nicardipine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Nicardipine
Frequently asked questions
Can I take Dihydroergotamine intranasal with Nicardipine?
MediHelp rates the interaction as major. Dihydroergotamine intranasal and Nicardipine can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Dihydroergotamine is cleared mainly by CYP3A4, and raised concentrations carry a risk of severe peripheral and cerebral vasospasm and ischemia. Nicardipine is only a modest CYP3A4 inhibitor, but the narrow safety margin of ergot toxicity makes the combination hazardous.
How serious is the interaction between Dihydroergotamine intranasal and Nicardipine?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid if possible and use an alternative migraine therapy. If used together, monitor for ischemic symptoms such as limb coldness, numbness and chest pain, and stop dihydroergotamine if they occur.
What other medicines interact with Nicardipine?
MediHelp also lists interactions of Nicardipine with, for example, Amifostine, Amlodipine-olmesartan-hydrochlorothiazide, Betrixaban. The full list is on the Nicardipine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
